Precigen (PGEN) Capital Leases (2012 - 2013)
Precigen's (PGEN) quarterly Capital Leases came in at $10000.0 in Q4 2013, down 76.19% year-on-year from $42000.0 in Q4 2012, and down 37.5% on a QoQ basis from $16000.0 in Q3 2013.
Precigen (PGEN) Capital Leases (2012 - 2013) Analysis & Trends
Precigen (PGEN) has 2 years of Capital Leases data on file, last reported at $10000.0 in Q4 2013.
- On a quarterly basis, Capital Leases fell 76.19% year-over-year to $10000.0 in Q4 2013; TTM through Dec 2013 was $10000.0, a 76.19% decrease from a year earlier, with the FY2013 full-year figure at $10000.0, down 76.19% from the prior year.
- Capital Leases for Q4 2013 stood at $10000.0, down from $16000.0 in the prior quarter.
- Over the last five years, Capital Leases for PGEN reached as high as $42000.0 in Q4 2012 and fell as low as $10000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Precigen | 1.96 Bn | 1.96 Bn | 20.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 10,000.00 |
| Sep 30, 2013 | 16,000.00 |
| Jun 30, 2013 | 25,000.00 |
| Dec 31, 2012 | 42,000.00 |